Member Info for Notposting

I love Pumpky. Great humour and zero harm intended. You lot are just reading far too much into it.

Honestly, if you truly believe in the science and the trajectory, a few daft comments on a bulletin board shouldn’t bother you one bit. Chill out. Objectivity is key in investing. Let the facts, not the chatter, guide your decisions.

No one here can change the ultimate outcome. If it works, the share price will reflect it. If it doesn’t, it won’t. In the end, the result is entirely out of our hands, so there is really no point getting worked up over noise.

Here he is again. How is the DSMB report you were going to read, Pingu?

“Vladik could sell HG CT 1 without treating another person and it would become the new standard of care delivered on half a dose.”

What a completely misleading statement and utter nonsense based against the phase 1 safety dose. Utterly speechless that anyone takes you lot seriously with such ridiculous statements.

Phase 1 trials exist precisely to establish a safe starting dose and to identify potential toxicities. Declaring a therapy the “new standard of care” without treating patients beyond that, without proper efficacy data, and without regulatory approval is not only scientifically reckless, it is fundamentally impossible.

Of all the idiotic statements you have made, this really beats it.

And that there… just ratifies my previous post JustHereForFleecing 🙂

#livinginyourheadrentfree

I don’t, because I’m not watching every day. I’m not a trader like you, so I don’t need live prices. I’ve never commented on the price except to temper the hype about a supposed £200m MCAP after the DSMB report or silly comments about pricing. Nice try at gaslighting, but that’s another miss to add to your list of incorrect claims and assumptions.

JustHereForFleecing. It’s quite something to hear you talk about ego-stroking or War and Peace, given your own posting record and misguided sense of self-importance. You say no one cares, yet you’re here all day replying and tracking every trade and price move. The irony in your posts today is comedy gold. 🤯

A bit rich, JHFH, considering your own posting history, the attacks, paranoia and continuously misleading comments/ or conspiracy nonsense you post to trade… not to mention the WhatsApp group. 😅😅😅

Ah, the old ‘no self-appointed moderators’ announcement delivered by a self-appointed moderator. Beautiful symmetry.

The only “twit” here seems to be you. Yet again, you’ve made a ridiculous claim that “no one actually sold,” when the share price and trade data clearly prove otherwise.

Your comments show a complete lack of understanding and only serve to mislead others. While I’m not suggesting there definitely are, you should at least know that deferred trades can legitimately be reported several days after execution.

And let’s drop the nonsense about people being “paid to post” on some amateur bulletin board. That’s pure fantasy like most of your posts.

It’s time to face reality, educate yourself on how markets actually function, and stop posting such embarrassing drivel in an attempt to sound informed.

Https://youtu.be/HS26Z1ELGU0?si=peZ5T7EDVqgTTMz3

Notposting

Posted in: HEMO

Posts: 198

Price: 860.00

No Opinion

RE: Interview

Today 15:38

Selective as always. Says a lot about a man’s character and about this board, which likes your selective summary but not a summary that is unbiased and provides a clear overview.

As you requested, here are the cons (I’ve posted the pros below because, unlike some, I’m not biased):

• There will be a delay, despite what the “LTHs claimed as fact,” as they need to transfer to Made. They prefer this to avoid sharing sensitive information, which adds extra time.

• Recruitment has not yet started.

• Funding will be required longer term. While they will look at the least dilutive methods, the recent raise indicates it came from less ideal sources, as they themselves said when consolidating at £4. The optimist would hope it may be licensed, but I suspect that won’t happen before the current runway ends.

• He has mentioned risks with DLTs, higher doses, and associated parties, points the hype crowd tends to ignore.

Recap of my original summary:

• Next dose escalation will involve adults-only cohorts.

• Delays are expected due to the transfer to Made before adult recruitment can commence.

• Up to 18 patients will be enrolled to determine the optimum and safest dose.

• The second arm will be children aged 12–18. Once the tech transfer is complete, recruitment will begin for the paediatric cohort at the lowest CAR-T dose.

• Each cohort will include 3 patients, provided there are no DLTs. Only 3 CAR-T doses will be used to treat these patients.

• Any DLT will require either an increase in patient numbers or a lower dose.

• Timing is uncertain. If all goes well, they expect to treat 1 adult and 1 paediatric patient per month. However, it’s unclear whether there will be toxicities at higher doses or how children will respond.

• Overall, this is a positive sign, though ultimately a Phase 2 trial will be needed to demonstrate efficacy.

• They are in discussions and could eventually either in-license or acquire.

• Exploring Estonia could generate revenue and provide additional data.

• They’ve raised £2.2 million. The company has a stable run rate but will need more funding.

• Share price reflects progress, having risen 4–5× over the last two months.

Thought I’d repost just so the “cohort” can spend the evening trying to cover it up. Not to mention none of the “LTHs” posted it, I did. They were probably too busy looking at L2. This was also in reply to the misleading post by “LetItRoll in favour of my trade”

That explains the anger. Sorry, they lied, and you got left behind holding the baby. I’m sure the time will come again as things develop, but they’ll have profited more trading at your cost, and you’ll definitely be a LTH now.

And HedgeHogarth, at what point have I slated the company, Vlad, the progress, or anything overall? Ah, I haven’t, but the WhatsApp group must be buzzing because I’ve called out one of your less-than-honest crew. I actually defended Vlad just a few posts prior, posts you’ve all descended on to hide coincidentally as it doesn’t suit your narratives, since it’s a balanced view.

The posts are there for all to see, including how “knowledgeable” or truthful he isn’t.

Take a breath, you sound a bit worked up. I’m sorry what he said didn’t happen or if they left you behind when cashing in the previous rise.

JustHereForFleecing: it’s impressive how full of delusion you are, completely empty of knowledge, yet somehow overflowing with mistruths, falsehoods, and fleecing fellow shareholders.

JustHereForFleecing. I wouldn’t know. I don’t have live data, unlike you. Wonder why you need it as a LTH or need to look at the trades? xx

Saint, I would agree with you.

Pingu is also the clown who was claiming he was looking forward to “reading” the DSMB report and that it would confirm efficacy, or is now claiming it is “working” based on a standard test in Phase 1 😂😂😂. You do have to wonder why all these companies spend millions on trials. They must be missing a trick.

JustHereForFleecing, as with most of the nonsense you make up, you are out of your depth and clearly clueless. I strongly suggest you get help and step away from the markets. Take the time to learn about Article 16(2) MAR and STOR/STR.

He comes across well. He isn’t the problem. The nonsense and hype people post here, along with the usual disingenuous cohort, is.

He gave an honest, grounded, and respectable interview.

JustHereForFleecing. It’s 16.6% down, a circa £8.5–9m drop in market cap, yet you claim there’s no large drop. Thinking traders have the power to make such shifts is idiotic at best, and plain delusion at worst. Go and learn the markets, please. Posts calling out “A” trades or traders. Absolute comedy, much like most of your posts that have proven to be falsehoods.

Selective as always. Says a lot about a man’s character and about this board, which like your selective summary but no likes on a summary that is unbiased and provides a clear overview.

As you requested, here are the cons (I’ve posted the pros below because, unlike some, I’m not biased):

• There will be a delay, despite what the “LTHs claimed as fact,” as they need to transfer to Made. They prefer this to avoid sharing sensitive information, which adds extra time.

• Recruitment has not yet started.

• Funding will be required longer term. While they will look at the least dilutive methods, the recent raise indicates it came from less ideal sources, as they themselves said when consolidating at £4. The optimist would hope it may be licensed, but I suspect that won’t happen before the current runway ends.

• He has mentioned risks with DLTs, higher doses, and associated parties, points the hype crowd tends to ignore.

Recap of my summary.

• Next dose escalation will involve adults-only cohorts.

• Delays are expected due to the transfer to Made before adult recruitment can commence.

• Up to 18 patients will be enrolled to determine the optimum and safest dose.

• The second arm will be children aged 12–18. Once the tech transfer is complete, recruitment will begin for the paediatric cohort at the lowest CAR-T dose.

• Each cohort will include 3 patients, provided there are no DLTs. Only 3 CAR-T doses will be used to treat these patients.

• Any DLT will require either an increase in patient numbers or a lower dose.

• Timing is uncertain. If all goes well, they expect to treat 1 adult and 1 paediatric patient per month. However, it’s unclear whether there will be toxicities at higher doses or how children will respond.

• It’s a good sign overall, though ultimately a Phase 2 trial will be needed to demonstrate efficacy.

• They are in discussions and could eventually either in-license or acquire.

• Looking at Estonia could generate revenue and provide additional data.

• They’ve raised £2.2 million. The company has a stable run rate but will need more funding.

• Share price reflects progress, having risen 4–5× over the last two months.

Less hype from Vlad himself. It just highlights how clueless some of these “LTHs” are with their misleading claims about there being no delays, no funding needed, and so on in their echo chambers to serve their trades.

Much rather stick to the facts.

Next dose escalation: adults only cohorts.

Delays are expected due to the transfer to Made before adult recruitment can commence.

Up to 18 patients will be enrolled to determine the optimum and safest dose.

The second arm will be children aged 12–18. Once the tech transfer is complete, recruitment will begin for the paediatric cohort at the lowest CAR-T dose.

Each cohort will include 3 patients, provided there are no DLTs. Only 3 CAR-T doses will be used to treat these patients.

Any DLT will require either an increase in patient numbers or a lower dose.

Not sure how long it will take. If all goes well, they expect to treat 1 adult and 1 paediatric patient per month. However, it’s uncertain whether there will be toxicities at higher doses or how children will respond.

It’s a good sign overall, though ultimately a Phase 2 trial will be needed to demonstrate efficacy.

They’re in discussions and eventually could either in-license or acquire.

Looking at Estonia - could generate revenue and provide additional data.

They’ve raised £2.2 million. The company has a stable run rate but will need more funding.

Share price reflects progress, having risen 4–5× over the last two months.